BerandaMOLN • SWX
add
Molecular Partners AG
Tutup sebelumnya
CHF 3,04
Rentang hari
CHF 2,92 - CHF 3,02
Rentang tahun
CHF 2,70 - CHF 6,80
Kapitalisasi pasar
120,52 jt CHF
Volume Rata-Rata
27,44 rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
SWX
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (CHF) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | — | — |
Biaya operasional | 16,14 jt | 259,35% |
Laba bersih | -16,77 jt | -48,09% |
Margin laba bersih | — | — |
Penghasilan per saham | -0,45 | — |
EBITDA | -15,59 jt | -2,21% |
Tarif pajak efektif | 0,01% | — |
Neraca
Total aset
Total liabilitas
| (CHF) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 130,91 jt | -24,82% |
Total aset | 141,10 jt | -23,98% |
Total liabilitas | 12,90 jt | -24,36% |
Total ekuitas | 128,19 jt | — |
Saham yang beredar | 37,27 jt | — |
Harga terhadap nilai buku | 0,88 | — |
Tingkat pengembalian aset | -26,94% | — |
Tingkat pengembalian modal | -29,41% | — |
Arus Kas
Perubahan kas bersih
| (CHF) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -16,77 jt | -48,09% |
Kas dari operasi | -17,08 jt | -0,18% |
Kas dari investasi | 34,96 jt | 98,53% |
Kas dari pembiayaan | -302,00 rb | -0,67% |
Perubahan kas bersih | 17,50 jt | 1.588,90% |
Arus kas bebas | -13,72 jt | -22,38% |
Tentang
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Didirikan
2004
Karyawan
159
